Mudassir Ali, MD
Psychiatry · Pleasanton, CANPI 1245278548
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Corium, LLC at 38.1% of the total. Reporting peaked in 2022 at $213 and has fallen 88.8% since, to $24 in 2024.
Across 22 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$152
- Johnson & Johnson$49
- Axsome Therapeutics, Inc.$40
- Otsuka America Pharmaceutical, Inc.$38
- Alkermes, Inc.$29
- AbbVie$24
- plus $67 from 3 others
What the payments were for
- Food & beverage$399100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 11 | $152 |
| Johnson & Johnson | 2 | $49 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Alkermes, Inc. | 1 | $29 |
| AbbVie | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
How this compares
$399 in reported general payments places this provider in the 60th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 12 | $5,494 |
| Olanzapine | 45 | $4,274 |
| Divalproex Sodium ErDivalproex Sodium | 16 | $2,065 |
| Bupropion XlBupropion Hcl | 47 | $868 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 16 | $438 |
| Escitalopram Oxalate | 49 | $332 |
| Paroxetine Hcl | 28 | $299 |
| Trazodone Hcl | 67 | $297 |
| Hydroxyzine Hcl | 13 | $279 |
| Sertraline Hcl | 38 | $269 |
| Lithium Carbonate ErLithium Carbonate | 20 | $229 |
| Bupropion Hcl | 11 | $62 |
| Clonazepam | 19 | $47 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Pleasanton
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.